Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2021-11-10 Earnings Release
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
8-K - Q3
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2021, reporting the financial results for the third quarter ended September 30, 2021. It includes a press release announcing recent business progress and third quarter financial results. The document explicitly states it is a current report and includes a press release as an exhibit. The length is 3763 characters, which is relatively short and the document mainly announces the release of financial results rather than containing detailed financial statements or analysis itself. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. Therefore, the appropriate classification is ER with high confidence.
2021-11-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-16 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-12 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-08 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2021, reporting the financial results for the second quarter ended June 30, 2021. It includes a press release announcing the financial results but does not contain the full financial statements or detailed financial analysis itself. The document length is 3680 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Since this document is a Form 8-K furnishing a press release announcing quarterly financial results, it fits the Earnings Release category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2021-08-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.